Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-01-26 4:23 pm Sale | 13D | BRIDGEBIO PHARMA INC BBIO | Eidos Therapeutics Inc. EIDX | 0 0% | -44,651,896 (Position Closed) | View |
| 2021-01-26 09:00 am Sale | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 1,000 100% | -24,574,501 (-100.00%) | View |
| 2020-10-15 4:17 pm Purchase | 13D | BRIDGEBIO PHARMA INC BBIO | Eidos Therapeutics Inc. EIDX | 44,651,896 36.4% | 44,651,896 (New Position) | View |
| 2020-10-06 4:45 pm Unchanged | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 34,510,971 28.2% | 0 (Unchanged) | View |
| 2020-10-05 5:30 pm Unchanged | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 24,575,501 63.7% | 0 (Unchanged) | View |
| 2020-06-01 5:09 pm Sale | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 34,510,971 28.4% | -2,389,690 (-6.48%) | View |
| 2020-02-14 4:21 pm Purchase | 13G | BRIDGEBIO PHARMA INC BBIO | PERCEPTIVE ADVISORS LLC | 6,706,268 5.4% | 120,000 (+1.82%) | View |
| 2020-02-14 4:00 pm Purchase | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 8,618,783 6.98% | 8,618,783 (New Position) | View |
| 2020-02-14 08:21 am Purchase | 13G | BRIDGEBIO PHARMA INC BBIO | AMERICAN INTERNATIONAL GROUP INC. AIG | 6,764,592 5.5% | 6,764,592 (New Position) | View |
| 2019-10-15 09:27 am Unchanged | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 24,575,501 65.6% | 0 (Unchanged) | View |
| 2019-08-08 4:11 pm Unchanged | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 24,575,501 66.6% | 0 (Unchanged) | View |
| 2019-07-11 5:00 pm Purchase | 13G | BRIDGEBIO PHARMA INC BBIO | PERCEPTIVE ADVISORS LLC | 6,586,268 5.5% | 6,586,268 (New Position) | View |
| 2019-07-10 5:06 pm Purchase | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 36,900,661 29.9% | 36,900,661 (New Position) | View |
| 2019-07-08 9:25 pm Purchase | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 24,575,501 66.73% | 882,353 (+3.72%) | View |
| 2019-07-08 4:46 pm Purchase | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 26,620,991 22.1% | 26,620,991 (New Position) | View |
| 2019-05-29 7:16 pm Purchase | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 23,693,148 64.3% | 1,103,848 (+4.89%) | View |